血浆β淀粉样蛋白在阿尔茨海默病早期诊断中的临床价值  

Clinical Value of Plasma β-amyloid in the Early Diagnosis of Alzheimer's Disease

作　　者：王治国[1] 战莹[1] 武晓丹[1] 郭佳[1] 陆国秀[1] 张彤[1] 张国旭[1] WANG Zhi-guo ZHAN Ying WU Xiao-dan GUO Jia LU Guo-xiu ZHANG Tong ZHANG Guo-xu(Department of Nuclear Medicine, General Hospital of Shenyang Military Area Command, Shenyang 110840, China)

机构地区：[1]沈阳军区总医院核医学科,辽宁沈阳110016

出　　处：《标记免疫分析与临床》2017年第9期976-978,共3页Labeled Immunoassays and Clinical Medicine

基　　金：辽宁省自然基金(20140220066)

摘　　要：目的探究血浆Aβ42、Aβ40和Aβ42/Aβ40比值作为生物标志物在阿尔茨海默病和轻度认知障碍早期诊断中的价值。方法入选受试者113例,其中44例阿尔茨海默病患者,33例轻度认知障碍患者和36例正常老年人,取静脉血测定其血浆Aβ42和Aβ40蛋白水平。结果 NC组、MCI组和AD组Aβ42水平和Aβ42/Aβ40比值逐渐下降。Aβ40水平逐渐升高,但差异无统计学意义。Aβ42水平可以区分NC组和AD组,但无法区分MCI组。Aβ40水平在各组之间比较差异无统计学意义。Aβ42/Aβ40比值在各组之间差异均具有统计学意义。结论血浆Aβ42和Aβ40不能独立作为阿尔茨海默病早期诊断标志物,而它们的比值或许可以作为潜在的MCI和AD的诊断生物标志物,作为脑脊液检查和影像学检查的补充作用。Objective To investigate the value of plasma Aβ42, Aβ40 and Aβ42 / Aβ40 ratios as biomarkers in the early diagnosis of Alzheimer′s disease and mild cognitive impairment.Methods A total of 113 subjects, of whom 44 with Alzheimer′s disease, 33 patients with mild cognitive impairment and 36 normal controls had their plasma Aβ42 and Aβ40 measured.Results We found that the ratio of Aβ42 and Aβ42 / Aβ40 in NC group, MCI group and AD group decreased gradually.Aβ40 level gradually increased with no statistically significant differences.Using Aβ42 levels, we can distinguish NC and AD but not MCI.There was no significant difference in the level of Aβ40 among the groups.Aβ42 / Aβ40 ratio among the groups were significantly different.Conclusion Plasma Aβ42 and Aβ40 can not be identified as early biomarkers for early diagnosis of Alzheimer′s disease independently.Their ratios may serve as potential biomarkers as a complementary effect of cerebrospinal fluid examination and imaging.

关 键 词：阿尔茨海默病 轻度认知障碍 淀粉样蛋白 AΒ42 Aβ40 

分 类 号：R749.16[医药卫生—神经病学与精神病学]